Pfizer (XSWX:PFE) Tariff Resilience Score: 6/10 (As of Jun. 27, 2026)


XSWX:PFE Pfizer Inc XSWX:PFE
59 GF Score
Price CHF19.62
GF Value CHF21.05
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Pfizer Tariff Resilience Score?

Pfizer XSWX:PFE 59 Tariff Resilience Score is 6 as of Jun. 27, 2026. GuruFocus rates XSWX:PFE with a GF Score™ of 59/100 and a GF Value™ of CHF21.05 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Pfizer ranks better than 90.98% on this metric.

Pfizer has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Pfizer has Pfizer has a global supply chain with manufacturing in multiple countries. While it faces some tariff risks, its diverse locations and strong pricing power mitigate impacts. Historical tariff changes have had limited effects due to its essential product nature.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Pfizer might have Average Resilient.

Pfizer  (XSWX:PFE) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Pfizer Tariff Resilience Score Related Terms

XSWX:PFE vs GILD, BMY, AMGN: Tariff Resilience Score Comparison

For the Drug Manufacturers - General subindustry, Pfizer's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pfizer Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pfizer's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Pfizer's Tariff Resilience Score falls into.


XSWX:PFE
59GF Score
Pfizer Inc XSWX:PFE
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Pfizer (XSWX:PFE) has a Tariff Resilience Score of 6 as of Jun. 27, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Pfizer ranks #93 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 9%.
Is Pfizer's Tariff Resilience Score too high?
Pfizer's current Tariff Resilience Score is 6. Based on the distribution chart, Pfizer ranks #93 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Pfizer has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pfizer's Tariff Resilience Score compare to GILD and BMY?
According to the Drug Manufacturers industry distribution chart, Pfizer ranks #93 out of 1031 companies for Tariff Resilience Score. This places Pfizer in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Pfizer's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Based on GuruFocus' analysis, Pfizer (XSWX:PFE) is currently considered Fairly Valued. The stock's GF Value™ is CHF21.05, compared to a current price of CHF19.62 — trading 6.8% below its estimated fair value. The current Tariff Resilience Score is 6. Pfizer's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Pfizer (XSWX:PFE), the current Tariff Resilience Score is 6 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pfizer (XSWX:PFE) Overvalued in 2026?

Based on GuruFocus' analysis, Pfizer stock appears to be undervalued. The current stock price of CHF19.62 is trading 6.8% below its estimated GF Value™ of CHF21.05. GuruFocus considers Pfizer to be Fairly Valued.

Key valuation signals for XSWX:PFE:

  • Tariff Resilience Score: 6
  • GF Value™: CHF21.05 vs. price of CHF19.62 (6.8% below fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the XSWX:PFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pfizer Business Description

Address 66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
59GF Score

Get the complete analysis for XSWX:PFE

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF19.62
Price
CHF21.05
GF Value